Natera secures regulatory clearance in Japan for its Signatera test, expanding market access for colorectal cancer detection.
Natera (NTRA) shares rose approximately 11% after Japan’s Pharmaceuticals and Medical Devices Agency approved its Signatera colorectal cancer test. The clearance allows Natera and its partner SRL, Inc. to market the test in Japan, broadening the company’s international footprint.
The approval follows growing demand for advanced diagnostic tools in oncology. Natera’s Signatera test is designed for personalized cancer monitoring, aligning with Japan’s push for precision medicine. No prior regulatory milestones in Japan were disclosed for this product.
The stock’s gain reflects investor optimism about revenue growth from new international markets.